Vaginal health takes center stage as Seed Health, a microbiome science company, unveils its latest innovation: VS-01 Vaginal Synbiotic. With a focus on redefining vaginal care, VS-01 represents a new vaginal synbiotic clinically validated to establish and sustain an optimal vaginal microbiome.
Developed in collaboration with renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01 aims to address the critical role of the vaginal microbiome in gynecological, urogenital, and reproductive health. Everyday factors such as stress, sex, menstruation, and diet can disrupt the delicate balance of the vaginal microbiome, leading to complications like infections, malodor, and inflammation. VS-01 seeks to restore this equilibrium by rapidly establishing an optimal vaginal microbiome dominated by Lactobacillus crispatus, a key protective bacteria.
The formulation of VS-01 is built upon Dr. Ravel’s extensive research, which has highlighted the importance of L. crispatus in maintaining vaginal health. Unlike other products that target only the symptoms, VS-01 takes a proactive approach by leveraging an ecology of three proprietary strains of L. crispatus. These strains, identified from over 600 candidate probiotic strains, demonstrate superior efficacy in maintaining regulated pH and promoting stability in vaginal health, according to the company.
“VS-01 embodies a new paradigm of care that empowers women to take control of their vaginal health,” stated Ara Katz, co-founder and co-CEO of Seed Health. “As a woman and a mother, I am especially proud to introduce an innovation that addresses a critical yet often overlooked aspect of women’s health. VS-01 represents the next frontier in vaginal care, offering a comprehensive solution backed by pioneering microbiome science.”
The launch of VS-01 expands Seed Health’s portfolio of microbiome-directed innovations and marks the company’s foray into the realm of vaginal health. With its commitment to translating cutting-edge science into life-changing health innovations, Seed Health aims to set a new standard in vaginal care. In addition to consumer applications, Seed Health is collaborating with Dr. Ravel under LUCA Biologics to develop live biotherapeutics targeting the vaginal microbiome for unmet needs in urogenital and reproductive health.
VS-01 Vaginal Synbiotic has undergone rigorous clinical validation, demonstrating its efficacy in restoring an optimal vaginal microbiome. In a double-blind, randomized, placebo-controlled clinical trial, 90% of participants established an optimal vaginal microbiome dominated by L. crispatus within 21 days of use. The formulation was also found to be well-tolerated and non-disruptive to the vaginal pH.
